FOXO4-DRI 10mg – 3ml Vial

Product Overview

FOXO4-DRI (D-Retro-Inverso) is a structurally modified peptide designed to interfere with the interaction between FOXO4 and p53 within cellular senescence models. The D-retro-inverso configuration enhances proteolytic stability while preserving functional binding characteristics in laboratory research systems.

In controlled in-vitro and pre-clinical studies, FOXO4-DRI is commonly utilised to investigate:

• p53–FOXO4 protein–protein interaction dynamics

• Cellular senescence signalling mechanisms

• Apoptosis pathway modulation in senescent cells

• Nuclear transcription factor binding models

• Ageing-associated molecular pathway research

Its D-amino acid retro-inverso structure provides increased resistance to enzymatic degradation in experimental systems, making it suitable for controlled mechanistic studies.

Supplied in lyophilised form to ensure structural stability and analytical purity prior to reconstitution.

Key Features

• Synthetic D-retro-inverso peptide analogue

• Studied in p53–FOXO4 interaction research

• Investigated in cellular senescence pathway models

• Enhanced proteolytic stability due to D-amino acid configuration

• ≥98% purity (HPLC verified)

• Lyophilised solid for enhanced stability

• 10mg per sterile 3ml glass vial

Product Specifications

• Product Name: FOXO4-DRI

• Synonyms: FOXO4 D-Retro-Inverso Peptide

• Molecular Class: Modified synthetic peptide (D-retro-inverso configuration)

• Amino Acid Sequence (3-Letter Code):
  D-Arg-D-Lys-D-Pro-D-Gly-D-Pro-D-Pro-D-Gly-D-Gly-D-Leu-D-Phe-D-Phe-D-Gly-D-Leu-D-Leu-D-Pro-D-Ser
  (D-retro-inverso analogue of the FOXO4 p53-binding domain)

• Molecular Formula: Complex modified peptide (exact formula dependent on salt form)

• Molecular Weight: ~2300 g/mol (approximate)

• CAS Number: Not formally assigned (research peptide analogue)

• Purity: ≥98% (HPLC)

• Appearance: White to off-white lyophilised powder

• Net Content: 10mg

• Vial Size: 3ml sterile glass vial

• Storage Form: Lyophilised peptide

• Intended Use: Laboratory research only

Handling & Storage Guidelines

Unreconstituted (Lyophilised) Storage:
Store at −20°C for long-term preservation. Short-term storage at 2–8°C is acceptable if intended for use within 1–3 months.

Reconstituted Storage:
After reconstitution, store at 2–8°C and use within 3–6 weeks. Stability may vary depending on solvent selection and handling conditions.

Avoid repeated freeze–thaw cycles. Protect from excessive agitation, heat, and direct light exposure.

Manufacturing & Quality

FOXO4-DRI is manufactured using advanced solid-phase peptide synthesis (SPPS) techniques under GMP-aligned laboratory standards.

Each batch undergoes:

• High Performance Liquid Chromatography (HPLC) purity verification

• Mass spectrometry identity confirmation

• Analytical quality control prior to release

• Batch traceability and documentation procedures

Products are released only after meeting strict internal quality specifications.

Legal & Safety Notice

This product is supplied strictly for laboratory research purposes only.

Not for human consumption.
Not for therapeutic, diagnostic, or veterinary use.
Not a licensed medicinal product in the United Kingdom.

The purchaser is responsible for ensuring full compliance with all applicable UK laws and regulations relating to research chemicals.